抗体-オリゴヌクレオチド結合体（AOC）の世界市場：2031年までの予測

世界の抗体-オリゴヌクレオチド結合体（AOC）の市場規模は、2026年の312万米ドルから2031年には2億9,141万米ドルに達し、予測期間（2026年～2031年）の年間平均成長率（CAGR）は147.78％になると予測されています。

米国・カナダの抗体-オリゴヌクレオチド結合体（AOC）の市場規模は、2026年の204万米ドルから2031年には1億6,503万米ドルに達し、予測期間（2026年～2031年）のCAGRは140.81%になると予測されています。

欧州の抗体-オリゴヌクレオチド結合体（AOC）の市場規模は、2026年の108万米ドルから2031年には9,695万米ドルに達し、2026年から2031年の予測期間中のCAGRは145.73%になると予測されています。

抗体-オリゴヌクレオチド結合体（AOC）の世界の主要企業には、Avidity Biosciences、Dyne Therapeutics、Tallac Therapeutics、Gennao Bio、ChainGen Bio、Denali Therapeuticsなどがあります。AOCの分野で技術革新が進むにつれ、競合も徐々に激化しています。特にがんや神経変性疾患の分野では、大手企業による新薬候補の上市が続いており、市場競争はますます激しくなっていくと思われます。

レポートの内容

抗体-オリゴヌクレオチド結合体（AOC）の世界市場規模を概観します。世界の市場動向を分析し、2020年～2024年の過去の市場収益データ、2024年の推定・予測、2031年までのCAGR予測を掲載しています。

抗体-オリゴヌクレオチド結合体（AOC）の主要生産者を調査し、主要地域・国の収益も掲載しています。抗体-オリゴヌクレオチド結合体（AOC）の今後の市場可能性の主なハイライトと、この市場を様々なセグメントとサブセグメントに分けて予測するための主要地域/国に焦点を当てます。米国、カナダ、メキシコ、ブラジル、中国、日本、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東・アフリカ、その他の国々の国別データと市場価値分析をまとめています。

当レポートでは、抗体-オリゴヌクレオチド結合体（AOC）の収益、市場シェア、主要企業の業界ランキングに焦点を当て、2020年から2024年までのデータを掲載しています。世界の抗体-オリゴヌクレオチド結合体（AOC）市場における主要利害関係者を特定し、最近の動向とセグメント別の収益に基づく競争環境と市場ポジショニングを分析します。当レポートは、利害関係者が競合情勢を理解し、より深い考察を得ることで、自社の事業や市場戦略をより良い形で位置づけるのに役立ちます。

当レポートでは、2020年から2031年までのタイプ別、用途別のセグメントデータ、収益、成長率を分析しています。抗体-オリゴヌクレオチド結合体（AOC）の収益、予測成長動向、生産技術、用途、エンドユーザー産業の市場規模の評価と予測されます。

目次

第1章 レポートの概要

• 調査範囲
• タイプ別市場分析
• 用途別市場
• 前提と制限
• 調査目的
• 対象年

第2章 世界の経済成長の動向

• 世界の抗体-オリゴヌクレオチド結合体（AOC）市場の見通し（2020年～2031年）
• 世界の抗体-オリゴヌクレオチド結合体（AOC）成長動向、地域別
• 抗体-オリゴヌクレオチド結合体（AOC）市場力学

第3章 主要参入企業による競合情勢

第4章 抗体-オリゴヌクレオチド結合体（AOC）の内訳データ、タイプ別

• 世界の抗体-オリゴヌクレオチド結合体（AOC）市場規模実績、タイプ別（2020年～2025年）
• 世界の抗体-オリゴヌクレオチド結合体（AOC）市場規模予測、タイプ別（2026年～2031年）

第5章 抗体-オリゴヌクレオチド結合体（AOC）の内訳データ、用途別

• 世界の抗体-オリゴヌクレオチド結合体（AOC）市場規模実績、用途別（2020年～2025年）
• 世界の抗体-オリゴヌクレオチド結合体（AOC）市場規模予測、用途別（2026年～2031年）

第6章 北米

第7章 欧州

第8章 中国

第9章 アジア（中国を除く）

第10章 中東・アフリカ、ラテンアメリカ

第11章 主要企業のプロファイル

• Avidity Biosciences
• Dyne Therapeutics
• Tallac Therapeutics
• Denali Therapeutics
• Gennao Bio
• ChainGen Bio

第12章 産業チェーンと販売チャネルの分析

• 抗体-オリゴヌクレオチド結合体（AOC）産業チェーン分析
• 抗体-オリゴヌクレオチド結合体（AOC）の主要原材料
• 抗体-オリゴヌクレオチド結合体（AOC）の販売およびマーケティング
• 抗体-オリゴヌクレオチド結合体（AOC）の顧客

第13章 アナリストの視点/結論

第14章 付録

List of Tables

• Table 1. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type (US$ Million): 2026 VS 2031
• Table 2. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth by Application (US$ Million): 2026 VS 2031
• Table 3. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2026 VS 2031
• Table 4. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025) & (US$ Million)
• Table 5. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2020-2025)
• Table 6. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031) & (US$ Million)
• Table 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2026-2031)
• Table 8. Antibody-oligonucleotide Conjugates (AOCs) Market Trends
• Table 9. Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
• Table 10. Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
• Table 11. Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
• Table 12. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2020-2025) & (US$ Million)
• Table 13. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Players (2020-2025)
• Table 14. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Headquarters and Area Served
• Table 15. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application
• Table 16. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry
• Table 17. Mergers & Acquisitions, Expansion Plans
• Table 18. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 19. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type (2020-205)
• Table 20. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031) & (US$ Million)
• Table 21. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type (2026-2031)
• Table 22. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 23. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application (2020-205)
• Table 24. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031) & (US$ Million)
• Table 25. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application (2026-2031)
• Table 26. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 27. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)
• Table 28. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 29. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)
• Table 30. North America Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Country (US$ Million): 2026 VS 2031
• Table 31. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
• Table 32. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
• Table 33. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 34. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)
• Table 35. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 36. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)
• Table 37. Europe Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Country (US$ Million): 2026 VS 2031
• Table 38. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
• Table 39. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
• Table 40. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 41. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)
• Table 42. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 43. China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)
• Table 44. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 45. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)
• Table 46. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 47. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)
• Table 48. Asia Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Region (US$ Million): 2027 VS 2031
• Table 49. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025) & (US$ Million)
• Table 50. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031) & (US$ Million)
• Table 51. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
• Table 52. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031) & (US$ Million)
• Table 53. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
• Table 54. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031) & (US$ Million)
• Table 55. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Growth Rate (CAGR) by Country (US$ Million): 2027 VS 2031
• Table 56. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
• Table 57. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
• Table 58. Avidity Biosciences Company Details
• Table 59. Avidity Biosciences Business Overview
• Table 60. Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 61. Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business 2026 VS 2031 & (US$ Million)
• Table 62. Avidity Biosciences Recent Development
• Table 63. Dyne Therapeutics Company Details
• Table 64. Dyne Therapeutics Business Overview
• Table 65. Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 66. Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)
• Table 67. Dyne Therapeutics Recent Development
• Table 68. Tallac Therapeutics Company Details
• Table 69. Tallac Therapeutics Business Overview
• Table 70. Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 71. Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)
• Table 72. Tallac Therapeutics Recent Development
• Table 73. Denali Therapeutics Company Details
• Table 74. Denali Therapeutics Business Overview
• Table 75. Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 76. Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)
• Table 77. Denali Therapeutics Recent Development
• Table 78. Gennao Bio Company Details
• Table 79. Gennao Bio Business Overview
• Table 80. Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 81. Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)
• Table 82. ChainGen Bio Company Details
• Table 83. ChainGen Bio Business Overview
• Table 84. ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product
• Table 85. ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031 & (US$ Million)
• Table 86. Raw Materials Key Suppliers Lists
• Table 87. Antibody-oligonucleotide Conjugates (AOCs) Customers List
• Table 88. Research Programs/Design for This Report
• Table 89. Key Data Information from Secondary Sources
• Table 90. Key Data Information from Primary Sources

List of Figures

• Figure 1. Antibody-oligonucleotide Conjugates (AOCs) Picture
• Figure 2. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type, (2020-2031) & (US$ Million)
• Figure 3. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type: 2026 VS 2031
• Figure 4. Site-specific Conjugation Picture
• Figure 5. Random Conjugation Picture
• Figure 6. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Application, 2026-2031 (US$ Million)
• Figure 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application: 2026 VS 2031
• Figure 8. Antibody-oligonucleotide Conjugates (AOCs) Report Years Considered
• Figure 9. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size (US$ Million), Year-over-Year: 2020-2031
• Figure 10. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size, (US$ Million), 2026 VS 2031
• Figure 11. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region: 2026 VS 2031
• Figure 12. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 13. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)
• Figure 14. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)
• Figure 15. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2026-2031)
• Figure 16. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 17. Canada Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 18. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 19. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)
• Figure 20. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)
• Figure 21. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2026-2031)
• Figure 22. Germany Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 23. France Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 24. U.K. Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 25. Italy Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 26. Russia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 27. China Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 28. China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2027-2031)
• Figure 29. China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)
• Figure 30. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 31. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)
• Figure 32. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)
• Figure 33. Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2020-2031)
• Figure 34. Japan Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 35. South Korea Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 36. Southeast Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 37. India Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 38. Australia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 39. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 40. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)
• Figure 41. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2020-2031)
• Figure 42. Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2027-2031)
• Figure 43. Mexico Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 44. Brazil Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 45. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
• Figure 46. Antibody-oligonucleotide Conjugates (AOCs) Value Chain
• Figure 47. Bottom-up and Top-down Approaches for This Report
• Figure 48. Data Triangulation
• Figure 49. Key Executives Interviewed

The global Antibody-oligonucleotide Conjugates (AOCs) market is projected to grow from US$ 3.12 million in 2026 to US$ 291.41 million by 2031, at a Compound Annual Growth Rate (CAGR) of 147.78% during the forecast period (2026-2031).

The US & Canada market for Antibody-oligonucleotide Conjugates (AOCs) is estimated to increase from $ 2.04 million in 2026 to reach $ 165.03 million by 2031, at a CAGR of 140.81% during the forecast period of 2026 through 2031.

The Europe market for Antibody-oligonucleotide Conjugates (AOCs) is estimated to increase from $ 1.08 million in 2026 to reach $ 96.95 million by 2031, at a CAGR of 145.73% during the forecast period of 2026 through 2031.

The global key companies of Antibody-oligonucleotide Conjugates (AOCs) include Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio and Denali Therapeutics, etc. As innovations continue to emerge in the field of AOCs, competition is also gradually intensifying. Major companies continue to launch new drug candidates, especially in the fields of cancer and neurodegenerative diseases, and the competition for market share will become more intense.

Report Includes

This report presents an overview of global market for Antibody-oligonucleotide Conjugates (AOCs) market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2024, and projections of CAGR through 2031.

This report researches the key producers of Antibody-oligonucleotide Conjugates (AOCs), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Antibody-oligonucleotide Conjugates (AOCs), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibody-oligonucleotide Conjugates (AOCs) revenue, market share and industry ranking of main companies, data from 2020 to 2024. Identification of the major stakeholders in the global Antibody-oligonucleotide Conjugates (AOCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Antibody-oligonucleotide Conjugates (AOCs) revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Avidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, Gennao Bio, ChainGen Bio and Denali Therapeutics, etc.

Market Segmentation

By Company

• Avidity Biosciences
• Dyne Therapeutics
• Tallac Therapeutics
• Denali Therapeutics
• Gennao Bio
• ChainGen Bio

Segment by Type

• Site-specific Conjugation

Random Conjugation

• Segment by Application
• Rare and Genetic Diseases
• Cancer Treatment
• Central Nervous System Disorders

By Region

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Rest of Europe
• Latin America
• Mexico
• Brazil
• Middle East & Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Antibody-oligonucleotide Conjugates (AOCs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antibody-oligonucleotide Conjugates (AOCs) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody-oligonucleotide Conjugates (AOCs) revenue, gross margin, and recent development, etc.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials and customers.

Chapter 13: Analyst's Viewpoints/Conclusions

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type: 2026 VS 2031
  • 1.2.2 Site-specific Conjugation
  • 1.2.3 Random Conjugation
• 1.3 Market by Application
  • 1.3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application: 2026 VS 2031
  • 1.3.2 Rare and Genetic Diseases
  • 1.3.3 Cancer Treatment
  • 1.3.4 Central Nervous System Disorders
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Perspective (2020-2031)
• 2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Growth Trends by Region
  • 2.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2026 VS 2031
  • 2.2.2 Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Region (2020-2025)
  • 2.2.3 Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031)
• 2.3 Antibody-oligonucleotide Conjugates (AOCs) Market Dynamics
  • 2.3.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Trends
  • 2.3.2 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
  • 2.3.3 Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
  • 2.3.4 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Revenue Antibody-oligonucleotide Conjugates (AOCs) by Players
  • 3.1.1 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2020-2025)
  • 3.1.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Players (2020-2025)
• 3.2 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs) Head office and Area Served
• 3.3 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application
• 3.4 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Type

• 4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Type (2020-2025)
• 4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031)

5 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Application

• 5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Application (2020-2025)
• 5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031)

6 North America

• 6.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
• 6.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
  • 6.2.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
  • 6.2.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
  • 6.2.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)
• 6.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
  • 6.3.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
  • 6.3.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
  • 6.3.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)
• 6.4 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country
  • 6.4.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031
  • 6.4.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
  • 6.4.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2026-2031)
  • 6.4.4 United States
  • 6.4.5 Canada

7 Europe

• 7.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
• 7.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
  • 7.2.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
  • 7.2.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
  • 7.2.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2026-2031)
• 7.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
  • 7.3.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
  • 7.3.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
  • 7.3.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2026-2031)
• 7.4 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country
  • 7.4.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031
  • 7.4.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
  • 7.4.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
  • 7.4.4 Germany
  • 7.4.5 France
  • 7.4.6 U.K.
  • 7.4.7 Italy
  • 7.4.8 Russia

8 China

• 8.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
• 8.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
  • 8.2.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
  • 8.2.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
  • 8.2.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2027-2031)
• 8.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
  • 8.3.1 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
  • 8.3.2 China Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
  • 8.3.3 China Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)

9 Asia (excluding China)

• 9.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
• 9.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
  • 9.2.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
  • 9.2.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
  • 9.2.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)
• 9.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
  • 9.3.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
  • 9.3.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
  • 9.3.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2027-2031)
• 9.4 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region
  • 9.4.1 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2027 VS 2031
  • 9.4.2 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025)
  • 9.4.3 Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031)
  • 9.4.4 Japan
  • 9.4.5 South Korea
  • 9.4.6 Southeast Asia
  • 9.4.7 India
  • 9.4.8 Australia

10 Middle East, Africa, and Latin America

• 10.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
• 10.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type
  • 10.2.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025)
  • 10.2.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2026-2031)
  • 10.2.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type (2020-2031)
• 10.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application
  • 10.3.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025)
  • 10.3.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2026-2031)
  • 10.3.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application (2020-2031)
• 10.4 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country
  • 10.4.1 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country: 2026 VS 2031
  • 10.4.2 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
  • 10.4.3 Middle East, Africa, and Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
  • 10.4.4 Mexico
  • 10.4.5 Brazil
  • 10.4.6 Middle East & Africa

11 Key Players Profiles

• 11.1 Avidity Biosciences
  • 11.1.1 Avidity Biosciences Company Details
  • 11.1.2 Avidity Biosciences Business Overview
  • 11.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.1.4 Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business 2026 VS 2031
  • 11.1.5 Avidity Biosciences Recent Development
• 11.2 Dyne Therapeutics
  • 11.2.1 Dyne Therapeutics Company Details
  • 11.2.2 Dyne Therapeutics Business Overview
  • 11.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.2.4 Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
  • 11.2.5 Dyne Therapeutics Recent Development
• 11.3 Tallac Therapeutics
  • 11.3.1 Tallac Therapeutics Company Details
  • 11.3.2 Tallac Therapeutics Business Overview
  • 11.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.3.4 Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
  • 11.3.5 Tallac Therapeutics Recent Development
• 11.4 Denali Therapeutics
  • 11.4.1 Denali Therapeutics Company Details
  • 11.4.2 Denali Therapeutics Business Overview
  • 11.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.4.4 Denali Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
  • 11.4.5 Denali Therapeutics Recent Development
• 11.5 Gennao Bio
  • 11.5.1 Gennao Bio Company Details
  • 11.5.2 Gennao Bio Business Overview
  • 11.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.5.4 Gennao Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031
• 11.6 ChainGen Bio
  • 11.6.1 ChainGen Bio Company Details
  • 11.6.2 ChainGen Bio Business Overview
  • 11.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Introduction
  • 11.6.4 ChainGen Bio Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business in 2031

12 Industry Chain and Sales Channels Analysis

• 12.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Chain Analysis
• 12.2 Antibody-oligonucleotide Conjugates (AOCs) Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Antibody-oligonucleotide Conjugates (AOCs) Sales and Marketing
• 12.4 Antibody-oligonucleotide Conjugates (AOCs) Customers

13 Analyst's Viewpoints/Conclusions

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
  • 14.1.2 Data Source
• 14.2 Author Details
• 14.3 Disclaimer 97